Literature DB >> 33441454

Memory Resilience in Alzheimer Disease With Primary Progressive Aphasia.

M-Marsel Mesulam1, Christina Coventry2, Alan Kuang2, Eileen H Bigio2, Qinwen Mao2, Margaret E Flanagan2, Tamar Gefen2, Jaiashre Sridhar2, Changiz Geula2, Hui Zhang2, Sandra Weintraub2, Emily J Rogalski2.   

Abstract

OBJECTIVE: To determine whether memory is preserved longitudinally in primary progressive aphasia (PPA) associated with Alzheimer disease (AD) and to identify potential factors that maintain memory despite underlying neurofibrillary degeneration of mediotemporal memory areas.
METHODS: Longitudinal memory assessment was done in 17 patients with PPA with autopsy or biomarker evidence of AD (PPA-AD) and 14 patients with amnestic dementia of the Alzheimer type with AD at autopsy (DAT-AD).
RESULTS: In PPA-AD, episodic memory, tested with nonverbal items, was preserved at the initial testing and showed no decline at retesting 2.35 ± 0.78 years later, at which time symptoms had been present for 6.26 ± 2.21 years. In contrast, language functions declined significantly during the same period. In DAT-AD, both verbal memory and language declined with equal severity. Although imaging showed asymmetric left-sided mediotemporal atrophy in PPA-AD, autopsy revealed bilateral hippocampo-entorhinal neurofibrillary degeneration at Braak stages V and VI. Compared to DAT-AD, however, the PPA-AD group had lower incidence of APOE ε4 and of mediotemporal TAR DNA-binding protein 43 (TDP-43) pathology.
CONCLUSIONS: Memory preservation in PPA is not just an incidental finding at onset but a core feature that persists for years despite the hippocampo-entorhinal AD neuropathology that is as severe as that of DAT-AD. Asymmetry of mediotemporal atrophy and a lesser impact of APOE ε4 and of TDP-43 on the integrity of memory circuitry may constitute some of the factors underlying this resilience. Our results also suggest that current controversies on memory in PPA-AD reflect inconsistencies in the diagnosis of logopenic PPA, the clinical variant most frequently associated with AD. CLINICALTRIALSGOV IDENTIFIER: NCT00537004 and NCT03371706.
© 2021 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33441454      PMCID: PMC8105903          DOI: 10.1212/WNL.0000000000011397

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  43 in total

1.  Cognitive impairment in Alzheimer's disease is modified by APOE genotype.

Authors:  Annelies E van der Vlies; Yolande A L Pijnenburg; Teddy Koene; Martin Klein; Astrid Kok; Philip Scheltens; Wiesje M van der Flier
Journal:  Dement Geriatr Cogn Disord       Date:  2007-06-26       Impact factor: 2.959

2.  Classification of primary progressive aphasia and its variants.

Authors:  M L Gorno-Tempini; A E Hillis; S Weintraub; A Kertesz; M Mendez; S F Cappa; J M Ogar; J D Rohrer; S Black; B F Boeve; F Manes; N F Dronkers; R Vandenberghe; K Rascovsky; K Patterson; B L Miller; D S Knopman; J R Hodges; M M Mesulam; M Grossman
Journal:  Neurology       Date:  2011-02-16       Impact factor: 9.910

Review 3.  Primary progressive aphasia.

Authors:  M M Mesulam
Journal:  Ann Neurol       Date:  2001-04       Impact factor: 10.422

4.  Neuropathologic basis of in vivo cortical atrophy in the aphasic variant of Alzheimer's disease.

Authors:  Daniel T Ohm; Angela J Fought; Alfred Rademaker; Garam Kim; Jaiashre Sridhar; Christina Coventry; Tamar Gefen; Sandra Weintraub; Eileen Bigio; Marek Marsel Mesulam; Emily Rogalski; Changiz Geula
Journal:  Brain Pathol       Date:  2019-09-12       Impact factor: 6.508

5.  Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.

Authors:  Abhinay D Joshi; Michael J Pontecorvo; Chrisopher M Clark; Alan P Carpenter; Danna L Jennings; Carl H Sadowsky; Lee P Adler; Karel D Kovnat; John P Seibyl; Anupa Arora; Krishnendu Saha; Jason D Burns; Mark J Lowrey; Mark A Mintun; Daniel M Skovronsky
Journal:  J Nucl Med       Date:  2012-02-13       Impact factor: 10.057

6.  Frequency of stages of Alzheimer-related lesions in different age categories.

Authors:  H Braak; E Braak
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

7.  Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia.

Authors:  M-Marsel Mesulam; Sandra Weintraub; Emily J Rogalski; Christina Wieneke; Changiz Geula; Eileen H Bigio
Journal:  Brain       Date:  2014-02-25       Impact factor: 13.501

8.  Assessing everyday memory in patients with dysphasia.

Authors:  J Cockburn; B Wilson; A Baddeley; R Hiorns
Journal:  Br J Clin Psychol       Date:  1990-11

9.  APOE is a correlate of phenotypic heterogeneity in Alzheimer disease in a national cohort.

Authors:  Sandra Weintraub; Merilee Teylan; Benjamin Rader; Kwun C G Chan; Mark Bollenbeck; Walter A Kukull; Christina Coventry; Emily Rogalski; Eileen Bigio; M-Marsel Mesulam
Journal:  Neurology       Date:  2019-11-08       Impact factor: 9.910

10.  Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report.

Authors:  Peter T Nelson; Dennis W Dickson; John Q Trojanowski; Clifford R Jack; Patricia A Boyle; Konstantinos Arfanakis; Rosa Rademakers; Irina Alafuzoff; Johannes Attems; Carol Brayne; Ian T S Coyle-Gilchrist; Helena C Chui; David W Fardo; Margaret E Flanagan; Glenda Halliday; Suvi R K Hokkanen; Sally Hunter; Gregory A Jicha; Yuriko Katsumata; Claudia H Kawas; C Dirk Keene; Gabor G Kovacs; Walter A Kukull; Allan I Levey; Nazanin Makkinejad; Thomas J Montine; Shigeo Murayama; Melissa E Murray; Sukriti Nag; Robert A Rissman; William W Seeley; Reisa A Sperling; Charles L White; Lei Yu; Julie A Schneider
Journal:  Brain       Date:  2019-06-01       Impact factor: 15.255

View more
  5 in total

Review 1.  Recent update on the heterogeneity of the Alzheimer's disease spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2021-12-17       Impact factor: 3.575

2.  Neuropathological fingerprints of survival, atrophy and language in primary progressive aphasia.

Authors:  M Marsel Mesulam; Christina A Coventry; Eileen H Bigio; Jaiashre Sridhar; Nathan Gill; Angela J Fought; Hui Zhang; Cynthia K Thompson; Changiz Geula; Tamar Gefen; Margaret Flanagan; Qinwen Mao; Sandra Weintraub; Emily J Rogalski
Journal:  Brain       Date:  2022-06-30       Impact factor: 15.255

3.  Communication Bridge™-2 (CB2): an NIH Stage 2 randomized control trial of a speech-language intervention for communication impairments in individuals with mild to moderate primary progressive aphasia.

Authors:  Angela C Roberts; Alfred W Rademaker; Elizabeth Ann Salley; Aimee Mooney; Darby Morhardt; Melanie Fried-Oken; Sandra Weintraub; Marsel Mesulam; Emily Rogalski
Journal:  Trials       Date:  2022-06-13       Impact factor: 2.728

4.  Neuroanatomical correlations of visuospatial processing in primary progressive aphasia.

Authors:  Boon Lead Tee; Christa Watson Pereira; Sladjana Lukic; Lynn P Bajorek; Isabel Elaine Allen; Zachary A Miller; Kaitlin B Casaletto; Bruce L Miller; Maria Luisa Gorno-Tempini
Journal:  Brain Commun       Date:  2022-03-14

Review 5.  Understanding the multidimensional cognitive deficits of logopenic variant primary progressive aphasia.

Authors:  Siddharth Ramanan; Muireann Irish; Karalyn Patterson; James B Rowe; Maria Luisa Gorno-Tempini; Matthew A Lambon Ralph
Journal:  Brain       Date:  2022-09-14       Impact factor: 15.255

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.